Meet the Experts

Patrick joined sixsense over seven years ago after spending 3 years as a life sciences headhunter with an executive search firm in downtown Toronto. Before this, he attended the University of Edinburgh, where he graduated with a BSc (Hons) and MSc in Neuroscience. Throughout his studies, Patrick had the opportunity to work in several research labs that focused on identifying the underlying mechanisms for various neurological diseases including multiple sclerosis and amyotrophic lateral sclerosis.

In his role as a Director, Science & Strategy, Patrick supports cross-functional teams at Canadian and US life sciences companies in the development of strategy. He has experience working across a significant number of therapeutic areas including neurology, hematology, and rare genetic diseases.

As well as being a foodie and amateur chef, Patrick is an avid rugby fan and can be found cheering for his provincial team in Ireland (Ulster) as well as the national team.

Thought Leadership

Medical Affairs
- Case Study: Redefining the Treatment Paradigm in Mental Health
  Our client was approaching the launch of a new product for treatment of a mental health disorder. Despite promising trial data, successful adoption of their therapy would be challenging for a number of reasons. Read the case study.
- Case Study: Strategic Launch in a Rare Hematologic Disease
  Learn how we navigated the challenges of launching a novel treatment in a rare hematologic disease to position our client's drug as a potential new standard of care. Read the full case study.
- Case Study: Development of a Scientific Platform for Biotech Client
  Our biotech client was facing the challenge of introducing a new competitor into the market while simultaneously gaining a deeper understanding of their disease state. To navigate this complex scenario, they needed a strategic document that would serve as the foundation for both internal and external communications.
- Case Study: KOL Identification and Engagement Planning in Rare Disease Clinical Development
  Our client, a leading biopharmaceutical company, sought to embark on a clinical development program within a new therapeutic area in the rare disease space. Read the case study.
- Article: Unveiling Insights: How KOLs Shaped a Groundbreaking Therapy’s Journey
  A recent pivotal Phase 3 clinical trial marked a significant milestone for our client, a biopharmaceutical company, in their quest to introduce a novel treatment for major depressive disorder (MDD). Read more.